Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc. (NASDAQ:NTRA), filed a Form 4 on November 4, 2026, disclosing the sale of 3,419 shares of common stock on November 2, 2026, under two separate Rule 10b5-1 arrangements.

Key Highlights

  • Reporting person: Solomon Moshkevich, President, Clinical Diagnostics at Natera, Inc.
  • Transaction date: November 2, 2026; 12 separate disposal transactions, all coded "S" (sale).
  • Total shares sold: 3,419 shares of common stock across all reported transactions.
  • Price range: Individual transaction prices ranged from $388.2001 per share to a weighted average of $416.4458 per share, depending on the tranche.
  • Post-transaction ownership: 101,323 shares of common stock held directly following all reported sales.
  • Two distinct plans: 419 shares were sold to satisfy tax withholding on RSU vesting under a plan tied to a Stock Unit Agreement granted January 31, 2025; 3,000 shares were sold under a Rule 10b5-1 trading plan adopted November 26, 2024.

Details of Moshkevich's November 2, 2026 Natera Share Disposals

According to the filing, Moshkevich disposed of shares in 12 separate tranches on November 2, 2026. The first two transactions, totaling 419 shares, were described as sales "effected in order to satisfy tax withholding and remittance obligations in connection with the vesting of RSUs," made pursuant to a written instruction intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, contained in a Stock Unit Agreement granted January 31, 2025. Those tranches were executed at $388.2001 per share (9 shares) and $400.2942 per share (410 shares).

The remaining 3,000 shares were sold across ten tranches pursuant to a separate Rule 10b5-1 trading plan adopted by Moshkevich on November 26, 2024. Per the filing, the prices reported for those tranches are weighted averages, with underlying per-share transaction prices ranging across the various sub-tranches from approximately $404.85 to $416.73. The filing notes that Moshkevich "undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price" within each reported range.

Following all 12 reported transactions, the filing indicates Moshkevich directly held 101,323 shares of Natera common stock. All ownership reported is direct. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports that Natera's President of Clinical Diagnostics, Solomon Moshkevich, sold a total of 3,419 shares of common stock on November 2, 2026, under two Rule 10b5-1 arrangements, retaining direct beneficial ownership of 101,323 shares.